Astrazeneca Farmaceutica Spain S.A.

4 trials 2 recruiting Commercial sponsor

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

2 Recruiting

2 Completed trials

1 Countries active

4 Unique IMPs

100% Results reported

Phase III

Phase II

Phase III/IV

Phase III: 2 Phase II: 1 Phase III/IV: 1

100%

2 of 2 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Small cell lung cancer 1

Top IMPs

DURVALUMAB 2 ACALABRUTINIB 1 CAPIVASERTIB 1 OLAPARIB 1

All trials

4 total

A study to evaluate acalabrutinib, in combination with the R-CHOP standard of care, for previously untreated mantle cell lymphoma in Spain. Recruiting

2025-521152-34-00 Phase II 1 country ACALABRUTINIB
Durvalumab after definitive chemoradiotherapy in limited stage small cell lung cancer Recruiting

2025-521340-37-00 Phase III 1 country DURVALUMAB
Research study on the use of capivasertib together with fulvestrant in patients with advanced breast cancer who have relapsed/progressed to … Ended

2024-513952-13-00 Phase III 1 country CAPIVASERTIB
Study to evaluate the use of durvalumab in combination with platinum-based chemotherapy followed by durvalumab with olaparib as first-line t… Ended

2024-514728-17-00 Phase III/IV 1 country DURVALUMAB; OLAPARIB

Showing 1–4 of 4 trials

← All sponsors A–Z